Search | Clinical Trials Finder

Conditions: Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP), Complicated Urinary Tract Infection (cUTI), Ventilator Associated Bacterial Pneumonia (VABP)
Interventions: Cefiderocol, Standard of Care; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Iowa City, Iowa • Fort Worth, Texas

Conditions: Corona Virus Infection, Cognitive Dysfunction
Interventions: Cognitive Training; Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Recipients of Liver Transplant
Interventions: Envarsus XR, Prograf; Drug
Lead sponsor: Methodist Healthcare - Memphis; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Soft Drink Consumption, Sugar-sweetened Beverages, Information Labels
Interventions: Nutrition Facts, Text Warning, Graphic Warning; Other
Lead sponsor: National Bureau of Economic Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 5,845 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Anxiety, Depression, Cannabis Use
Interventions: CC, PAC, WL; Behavioral
Lead sponsor: Trustees of Dartmouth College; Other
Eligibility: 21 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
Interventions: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension; Drug · Diagnostic Test · Genetic
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma, Primary Mediastinal B-cell Lymphoma
Interventions: JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 14
States / cities: Birmingham, Alabama • Duarte, California • San Francisco, California + 10 more

Conditions: Melanoma (Skin)
Interventions: paclitaxel albumin-stabilized nanoparticle formulation; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Weight Stigma
Interventions: Nutrient warning labels, Text-only health warning labels, Graphic health warning labels, Control labels; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years and older
Enrollment: 2,522 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: AML
Interventions: Quizartinib, Salvage Chemotherapy; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 36
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 31 more

Conditions: Health, Wellness, Quality of Life
Interventions: A ready-to-mix beverage containing protein, fiber, and electrolytes; Dietary Supplement
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Eltrombopag, Avatrombopag, Standard of care; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Watertown, South Dakota

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: 3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI; Drug · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: Spire Health Monitor; Device
Lead sponsor: Spire, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: ADHD - Attention Deficit Disorder With Hyperactivity, Irritability, Aggression Childhood
Interventions: CNS Stimulant, Placebo, CNS Stimulant open label first phase; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 7 Years to 12 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease, Secondary Hyperparathyroidism
Interventions: cinacalcet capsule, placebo, Standard of Care; Drug
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more

Conditions: Non-Small Cell Lung Cancer
Interventions: NKTR-214, Pembrolizumab, Cisplatin, Carboplatin, Nab paclitaxel, Paclitaxel, Pemetrexed, Atezolizumab; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 23
States / cities: Fayetteville, Arkansas • San Francisco, California • Aurora, Colorado + 19 more

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: GlycosBio Nutritional Supplement + PERT placebo, Standard Nutritional Supplement + PERT; Dietary Supplement
Lead sponsor: GlycosBio, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: FDG-PET, ASL-MRI, Lumbar Puncture; Drug · Other · Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 55 Years to 89 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Ischemic Stroke
Interventions: Endovascular Thrombectomy, Medical Management; Device · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 19
States / cities: Los Angeles, California • Jacksonville, Florida • Chicago, Illinois + 14 more

Conditions: Knee Arthritis, Knee Osteoarthritis, Knee Pain Chronic, Knee Discomfort, Rheumatoid Arthritis, Knee Pain Swelling
Interventions: Gold Factor (Gold Nanoparticles, AuNPs), Placebo; Dietary Supplement
Lead sponsor: 4Life Research, LLC; Industry
Eligibility: 18 Years to 87 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prehypertension
Interventions: Labeled prehypertension, Unlabeled prehypertension; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
Interventions: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2); Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2033
U.S. locations: 30
States / cities: Duarte, California • Glendale, California • Los Angeles, California + 25 more

Conditions: Cholesterol, Triglycerides, Omega-3, Eicosapentaenoic Acid
Interventions: AlmegaPL (FDA NDIN # 826); Dietary Supplement
Lead sponsor: Qualitas Health; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Tempe, Arizona • Houston, Texas

Search by objective public record fields.

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants

Computer Cognitive Training for Post-acute COVID-19 Syndrome

Envarsus XL Immunosuppression Following Liver Transplantation

Are Sugar-Sweetened Beverage Information Labels Well-Targeted

Evaluating the Impact of Psychotherapeutic Advertising Claims on Cannabis Purchasing

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

Impact of Front-of-package Warning Labels on Perceived Weight Stigmatization

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

An Open Label Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on GI Health and Related Health Outcomes

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

Spire Health Remote Patient Monitor Human Factors Summative Study Protocol

Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants

Pediatric Chronic Kidney Disease Safety and Efficacy

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis

Arterial Spin Labeling (ASL) MRI for Cognitive Decline

SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

Gold Factor on Knee Joint Health and Function

Prehypertension Labeling

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

AlmegaPL CV Health Open Label Study